Elucidating the Action Mechanism of Shenling Baizhu Powder in the Treatment of Ulcerative Colitis Based on Network Pharmacology andExperimental Validation

SLBZ exerts therapeutic effects on UC by targeting key proteins (e.g., TP53, AKT1, JUN) and modulating critical pathways (e.g., JAK2/STAT3). This study provides a theoretical basis for the potential of SLBZ as a multi-targeted therapeutic agent for UC, which can be further explored through clinical trials and multi-omics analyses to validate its efficacy and safety.